QL1206 clinical trials
Also written QL1206.
A product of Denosumab; its studies count on that page too.
How each study uses QL1206 is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Get an email when these change. Save the QL1206 studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your alerts, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your alerts. Stop any time.
Approvals
The first approval found in each region, with its record
- United States
- 1 Jun 2010 · PROLIA · BLA 125320 (FDA, Drugs@FDA; as Denosumab)
- European Union
- 26 May 2010 · Prolia · EMEA/H/C/001120 (EMA; as Denosumab)
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Development codes
- QL1206
- 5
Studies by the year they started
5 studies that test it; most in 2019 (3)
| Year | Studies |
|---|---|
| 2018 | 1 |
| 2019 | 3 |
| 2025 | 1 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 5 · Other 0
Related medicines
As reviewed, each with the page that says it.
- A brand or code of Denosumab
Coming up
From the study records. Dates are the sponsors’ own estimates and often move.
Reaching primary completion within a year · 1, 1 in phase 3
Studies that test QL1206, phase 3 first.
- Jan 2027A Comparative Study to Valuating the Efficacy and Safety of QL1206 and Prolia®Phase 3 · Qilu Pharmaceutical Co., Ltd.
Studies
Open first, then newest update. How each study uses QL1206 is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 5
- A Comparative Study to Valuating the Efficacy and Safety of QL1206 and Prolia®RecruitingPhase 3Qilu Pharmaceutical Co., Ltd.NCT07062978Written as QL1206
- To Evaluate the Efficacy and Safety of QL1206 and Xgeva in Patients With Bone Metastases From Solid TumorsStatus unknownPhase 3Qilu Pharmaceutical Co., Ltd.NCT04550949Written as QL1206
- Comparing of the Pharmacokinetic, Safety and Pharmacodynamic of QL1206 and Prolia® in Healthy AdultsStatus unknownPhase 1Qilu Pharmaceutical Co., Ltd.NCT04213105Written as QL1206
- Efficacy and Safety of QL1206 in the Treatment of Postmenopausal Osteoporosis With High Fracture RiskStatus unknownPhase 3Qilu Pharmaceutical Co., Ltd.NCT04128163Written as QL1206
- Comparing of the Pharmacokinetic, Safety and Pharmacodynamic of QL1206 and Xgeva® in Healthy AdultsCompletedPhase 1Qilu Pharmaceutical Co., Ltd.NCT03651947Written as QL1206